Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Report Description
Healthcare professionals focuses on the treatment of liver fibrosis by treating the cause of liver fibrosis, to stops or slows scarring of the liver. Chronic alcohol drinking, autoimmune hepatitis, storage and metabolism disorders such as Wilson disease, Galactosemia, Fructosemia, glycogen storage diseases, iron-overload symptoms, Gaucher disease, some of the bacterial, parasite and viral infections, disorders affecting hepatic blood flow, among others are some of the possible risk factors associated with liver fibrosis management. Furthermore, liver fibrosis treatment market is witnessing increased pace in the NASH treatment.
The underlining prevalence cases of Non-alcoholic Steatohepatitis (NASH) are expected to increase in future with increasing number of population consuming high fat diet. Increasing obesity and diabetes epidemics, liver fibrosis, and NASH are expected to drive market growth, as key players are focused on developing treatment for this disorders.
Market Dynamics
Increasing incidence of liver fibrosis, along with growing prevalence of risk factors such as chronic infection with hepatitis B or C virus, compromised immune system due to co-infection with HIV or use of immunosuppressive drugs after a liver transplant are expected to fuel growth of the liver fibrosis treatment market. Furthermore, growing collaborations and research in order to treat liver fibrosis are expected to spur the liver fibrosis treatment market growth. For instance, in October 2015, professors from University of Newcastle made collaboration with GlaxoSmithKline (GSK) plc to develop drugs, which can stop or reverse liver fibrosis. The aim of collaboration with GSK is to identify existing drugs and develop new compounds, which target myofibroblasts in the treatment of liver fibrosis.
Key features of the study:
• This report provides in-depth analysis of liver fibrosis treatment market, its market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017, as the base year.
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launch or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global liver fibrosis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics
• The global liver fibrosis treatment market report caters to various stakeholders in this industry including investors, researchers, liver fibrosis treatment drug manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the liver fibrosis treatment market.
Detailed Segmentation:
• Global Liver Fibrosis Treatment Market, By Treatment Type:
o Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
o ACE Inhibitors
o Hepatotropic Drug
o Others
• Global Liver Fibrosis Treatment Market, By Condition:
o Chronic Liver Diseases
o Hepatitis C
o Nonalcoholic Steatohepatitis
• Global Liver Fibrosis Treatment Market, By End User:
o Hospitals
o Specialty Clinics
o Retail Pharmacy
• Global Liver Fibrosis Treatment Market, By Geography:
o North America
o By Country:
• U.S.
• Canada
o By Treatment Type:
o Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
o ACE Inhibitors
• Hepatotropic Drug
o By Condition:
• Chronic Liver Diseases
• Hepatitis C
• Nonalcoholic Steatohepatitis
o By End User:
• Hospitals
• Specialty Clinics
• Others
o Europe
o By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
o By Treatment Type:
• Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
• ACE Inhibitors
• Hepatotropic Drug
o By Condition:
• Chronic Liver Diseases
• Hepatitis C
• Nonalcoholic Steatohepatitis
o By End User:
• Hospitals
• Specialty Clinics
• Others
o Asia Pacific
o By Country:
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
o By Treatment Type:
• Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
• ACE Inhibitors
o By Condition:
• Chronic Liver Diseases
• Hepatitis C
• Nonalcoholic Steatohepatitis
• Hepatotropic Drug
o By End User:
• Hospitals
• Specialty Clinics
• Others
o Latin America
o By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
o By Treatment Type:
• Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
• ACE Inhibitors
• Hepatotropic Drug
o By Condition:
• Chronic Liver Diseases
• Hepatitis C
• Nonalcoholic Steatohepatitis
o By End User:
• Hospitals
• Specialty Clinics
• Others
o Middle East
o By Country:
• GCC
• Israel
• Rest of Middle East
o By Treatment Type:
• Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
• ACE Inhibitors
• Hepatotropic Drug
o By Condition:
• Chronic Liver Diseases
• Hepatitis C
• Nonalcoholic Steatohepatitis
o By End User:
• Hospitals
• Specialty Clinics
• Others
o Africa
o By Country:
• North Africa
• Central Africa
• South Africa
o By Treatment Type:
• Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
• ACE Inhibitors
• Hepatotropic Drug
o By Condition:
• Chronic Liver Diseases
• Hepatitis C
• Nonalcoholic Steatohepatitis
o By End User:
• Hospitals
• Specialty Clinics
• Others
• Company Profiles
o Gilead Sciences, Inc.*
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments
o Strategies
o Merck & Co., Inc.
o Bristol-Myers Squibb
o Johnson and Johnson
o Novartis AG
o Vertex Pharmaceuticals Incorporated
o Pfizer Inc.
o FibroGen, Inc.
o Pharmaxis Limited
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Treatment Type
o Market Snippet, By End User
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o Market Trends
o New Drug Approvals
o Strategic Collaborations
o Drug Pipeline Analysis
o Regulatory Scenario
o PEST Analysis
4. Global Liver Fibrosis Treatment Market, By Treatment Type, 2016 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o ACE Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Hepatotropic Drug
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
5. Global Liver Fibrosis Treatment Market, By Condition, 2016 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Chronic Liver Disease
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Hepatitis C
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Nonalcoholic Steatohepatitis
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
6. Global Liver Fibrosis Treatment Market, By End User, 2016 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Hospitals
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Specialty Clinics
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
7. Global Liver Fibrosis Treatment Market, By Region, 2016 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, By Region, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, By Region, 2017 - 2026
o North America
o Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Condition, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• U.S.
• Canada
o Europe
o Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Condition, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Condition, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• China
• Japan
• India
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
o Latin America
o Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Condition, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
o Africa
o Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Condition, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• Northern Africa
• Central Africa
• South Africa
o Middle East
o Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Condition, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By End User, 2016 - 2026, (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
• GCC Countries
• Israel
• Rest of Middle East
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profiles
o Gilead Sciences, Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
o Merck & Co., Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
o Bristol-Myers Squibb
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
o Johnson and Johnson
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
o Novartis AG
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
o Vertex Pharmaceuticals Incorporated
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
o Pfizer Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
o FibroGen, Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
o Pharmaxis Limited
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
9. Analyst Views
10. Section
o References
o Research Methodology
o About Us and Sales Contact
*Browse 24 market data tables and 28 figures on "Liver Fibrosis Treatment Market - Global forecast to 2026".
